Liquid biopsies results compared with clinical outcomes

Exosome Diagnostics, Inc., and MD Anderson Cancer Center had a unique study published in Clinical Cancer Research, a peer reviewed publication of the American Association of Clinical Cancer Research. The analysis directly compared Exosome Diagnostics’ ExoLution® Plus platform with two different platforms, BEAMing and ddPCR, analysing cfDNA alone. Teams at MD Anderson Cancer Center and Exosome Diagnostics showed that the ExoLution Plus platform, which simultaneously analyses exoNA and cfDNA correlated better to clinical outcome than cfDNA analysis alone in a cohort of 43 patients with progressive advanced cancer. The teams studied overall survival among the patients and linked low amounts of mutated exosome nucleic acids (exoNA) with longer survival times and high amounts of mutated exoNA with shorter survival times.

“Our study reports two novel observations. First, our data suggest that next-generation sequencing of plasma-derived exosomal nucleic acids from patients with advanced cancers has high sensitivity compared to molecular testing of plasma cell-free DNA or archival tumor samples. Second, we demonstrated that the amount of mutated exosomal nucleic acids is an independent prognostic factor for survival” said Filip Janku, senior author on the study (MD Anderson Cancer Center.)

“Exosomal nucleic acid performed better than cfDNA irrespective if the cfDNA analysis was done using sensitive platforms such as ddPCR and BEAMing, possibly due to the fact that exosomes originates from living cancer cells vs cfDNA from dead cancer cells”, said Johan Skog, Chief Scientific Officer at Exosome Diagnostics.

“This publication is further validation of the ExoDx’s proprietary platform superiority to cfDNA platforms.” Stated, John Boyce, President and CEO. “Our team has spent the last several years doing direct comparisons of ExoLution Plus to competitive cfDNA and other exosome RNA isolation platforms and have always demonstrated the superior performance of the ExoDx platform whether it is outcome correlation, superior mutation detection, or quantity / quality of RNA found,” Boyce continued. “This strengthens our leadership position in the liquid biopsy space with technology that will translate to superior diagnostic tests for better healthcare.”

 Overall survival (OS) per mutation allelic frequency (MAF) of KRAS, BRAF, or EGFR mutations in plasmaexosomes

A, Twenty-one patients with a low MAF (≤median; blue dashed line) in plasma exoNA had a significantly longer median OS duration than 22 patients with a high MAF  (>median; red line; 11.8 vs. 5.9 months; P=0.006). B, There was a trend for 21 patients with a low MAF (blue dashed line) in plasma cfDNA tested with droplet digital PCR to have a longer median OS than 20 patients with a high MAF (red line; 8.5 vs. 5.9 months; P=0.023). C, There was a trend for 19 patients with a low MAF (blue dashed line) in plasma cfDNA tested with BEAMing to have a longer median OS than 18 patients with a high MAF (red line; 7.4 vs. 6.5 months; P=0.066).

Source – Globe Newswire

Möhrmann L, Huang H, Hong DS, Tsimberidou AM, Fu S, Piha-Paul S, Subbiah V, Karp DD, Naing A, Krug AK, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. (2017) Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res [Epub ahead of print]. [abstract]

Leave a Reply

Your email address will not be published. Required fields are marked *

*